PAKOLA STEVE sold $689K of RGNX
PAKOLA STEVE (Chief Medical Officer) sold 56,333 shares of REGENXBIO Inc. (RGNX) at an average of $12.23 ($11.04–$12.86, $0.69M total) across 2 trades over 2026-06-29 to 2026-07-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a concrete datapoint on insider selling activity, but it does not include new clinical, regulatory, or financial guidance information.
Market read
Traders may monitor for follow-on insider activity, but the 10b5-1 context reduces the signal strength.
What to watch
Insider sales can be misread; traders should check whether the plan size/pace is typical versus unusual, and whether any other contemporaneous filings (buys, grants, guidance) exist.
Background
The article is an SEC Form 4 insider transaction disclosure for Regenxbio (RGNX).
Ticker impact
Regenxbio insider Chief Medical Officer Pakola Steve sold $688,755 of RGNX stock via a 10b5-1 plan (Form 4).
Low likelihood of a sustained price move; any reaction is likely muted and short-lived.
The filing is a routine open-market sale under a pre-arranged 10b5-1 plan, with no accompanying operational or guidance change disclosed.
Market effects
Minimal; single-company insider transaction without sector-wide signal.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.
Key entities
- public_companyREGENXBIO Inc.
Issuer of the insider transaction disclosed on SEC Form 4.
- insiderPAKOLA STEVE
Chief Medical Officer who executed open-market sales under a pre-arranged 10b5-1 plan.
